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Abstract
Background: Meta-analysis of continuous outcomes traditionally uses mean difference (MD) or
standardized mean difference (SMD; mean difference in pooled standard deviation (SD) units). We
recently used an alternative ratio of mean values (RoM) method, calculating RoM for each study
and estimating its variance by the delta method. SMD and RoM allow pooling of outcomes
expressed in different units and comparisons of effect sizes across interventions, but RoM
interpretation does not require knowledge of the pooled SD, a quantity generally unknown to
clinicians.
Objectives and methods: To evaluate performance characteristics of MD, SMD and RoM using
simulated data sets and representative parameters.
Results: MD was relatively bias-free. SMD exhibited bias (~5%) towards no effect in scenarios with
few patients per trial (n = 10). RoM was bias-free except for some scenarios with broad
distributions (SD 70% of mean value) and medium-to-large effect sizes (0.5–0.8 pooled SD units),
for which bias ranged from -4 to 2% (negative sign denotes bias towards no effect). Coverage was
as expected for all effect measures in all scenarios with minimal bias. RoM scenarios with bias
towards no effect exceeding 1.5% demonstrated lower coverage of the 95% confidence interval
than MD (89–92% vs. 92–94%). Statistical power was similar. Compared to MD, simulated
heterogeneity estimates for SMD and RoM were lower in scenarios with bias because of decreased
weighting of extreme values. Otherwise, heterogeneity was similar among methods.
Conclusion: Simulation suggests that RoM exhibits comparable performance characteristics to
MD and SMD. Favourable statistical properties and potentially simplified clinical interpretation
justify the ratio of means method as an option for pooling continuous outcomes.
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Background
Meta-analysis is a method of statistically combining
results of similar studies [1]. For binary outcome variables
both difference and ratio methods are commonly used.
For each study, the risk difference is the difference in pro-
portions of patients experiencing the outcome of interest
between the experimental and control groups, the risk
ratio is the ratio of these proportions, and the odds ratio
is the ratio of the odds. Meta-analytic techniques are used
to combine each study's effect measure to generate a
pooled effect measure. Standard meta-analytic procedures
for each of these effect measures also estimate heterogene-
ity, which is the variability in treatment effects of individ-
ual trials beyond that expected by chance. Each effect
measure (risk difference, risk ratio, odds ratio) has advan-
tages and disadvantages in terms of consistency, mathe-
matical properties, and ease of interpretation, implying
that none is universally optimal [2].
In contrast, for continuous outcome variables, only differ-
ence methods are commonly used for group comparison
studies [3]. If the outcome of interest is measured in iden-
tical units across trials, then the effect measure for each
trial is the difference in means, and the pooled effect
measure is the mean difference (MD), which more accu-
rately should be described as the weighted mean of mean
differences. If the outcome of interest is measured in dif-
ferent units, then each trial's effect measure is the differ-
ence in mean values divided by the pooled standard
deviation of the two groups, and the pooled effect meas-
ure is the standardized mean difference (SMD), which
more accurately should be described as the weighted
mean of standardized mean differences. Normalizing the
differences using the standard deviation allows pooling of
such results, in addition to allowing comparison of effect
sizes across unrelated interventions. By convention [4],
SMD's of 0.2, 0.5, and 0.8 are considered "small",
"medium", and "large" effect sizes, respectively. When tri-
als in meta-analyses are weighted by the inverse of the var-
iance of the effect measure (the weighting scheme
generally used for MD and SMD), the pooled SMD has the
unfavorable statistical property of negative bias (i.e.
towards the null value) [5,6]. Alternative methods of esti-
mating the variance of individual trial SMDs used in the
inverse variance method have been proposed to minimize
this bias [5,6].
In principle, meta-analysts could also use ratio methods
to analyze continuous outcomes, by calculating a ratio of
mean values instead of a difference. Since the ratio is unit-
less, this calculation can be carried out regardless of the
specific units used in individual trials. Moreover, as with
SMD, a ratio can be used to combine related but different
outcomes (e.g. quality of life scales). We have recently
used this Ratio of Means (RoM) method in meta-analyses
[7-9] in which we estimated the variance of this ratio
using the delta method [10]. For this method, each indi-
vidual study RoM is converted to its natural logarithm
before being pooled, and the pooled result is then back
transformed, similar to odds and risk ratio calculations
used for binary outcomes. Table 1 presents the pooled
results for the continuous variables from the meta-analy-
sis of low-dose dopamine for renal dysfunction [7], ana-
lyzed using mean difference methods and the RoM
Table 1: Renal Physiological Parameters from Low-Dose Dopamine Meta-Analysis 1 Day After Starting Therapy [7].
Effect Measure
Parameter Number of Trials Number of Patients MD SMD RoM
Urine Output 33 1654 Estimate -- 0.49 1.24
95% CI -- 0.29 to 0.69 1.14 to 1.35
p-value -- <0.001 <0.001
I2 -- 71% 77%
Serum Creatinine 32 1807 Estimate -3.51 -0.28 0.96
95% CI -6.71 to -0.23 -0.51 to -0.06 0.93 to 0.99
p-value 0.04 0.01 0.01
I2 73% 79% 73%
Creatinine Clearance 22 1077 Estimate -- 0.10 1.06
95% CI -- -0.02 to 0.22 1.01 to 1.11
p-value -- 0.10 0.02
I2 -- 0% 0%
The pooled effect measure results are presented along with their 95% confidence intervals and null hypothesis p-values for each of the three renal 
physiological variables evaluated in the meta-analysis, urine output, serum creatinine, and creatinine clearance, 1 day after the start of therapy. The 
degree of heterogeneity, expressed using the I2 statistic for each of the pooled effect measures for each of the variables is also shown. For urine 
output and creatinine clearance, MD could not be used because units differed across studies. In contrast, all serum creatinine values were 
expressed as or could be converted to identical units (μmol/L), allowing this variable to also be analyzed using MD.
Abbreviations: CI – confidence interval, I2 – I2 heterogeneity statistic, MD – mean difference, RoM – ratio of means, SMD – standardized mean 
differenceBMC Medical Research Methodology 2008, 8:32 http://www.biomedcentral.com/1471-2288/8/32
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method, in addition to heterogeneity expressed using the
I2 measure. (I2 is the percentage of total variation in results
across studies due to heterogeneity rather than chance
[11,12].) Table 1 shows similar results among the three
methods. The point estimates are similar in direction (i.e.
a positive mean difference or standardized mean differ-
ence corresponds to a RoM greater than one, while a neg-
ative mean difference corresponds to a RoM less than
one). The confidence intervals result in similar p-values
for statistically significant increases or decreases for each
of these parameters. Finally, heterogeneity is similar.
Given the similarity of these results, the objective of this
current study was to test the hypothesis that MD, SMD,
and RoM methods exhibit comparable performance char-
acteristics in terms of bias, coverage and statistical power,
using simulated data sets with a range of parameters com-
monly encountered in meta-analyses.
Methods
The RoM Effect Measure
For mean difference meta-analysis, one calculates a differ-
ence in mean values between the experimental and con-
trol groups for each study. (A review of the inverse-
variance weighted fixed and random effects models and
calculation of the point estimates and variances for MD
and SMD using standard methods [including a correction
factor for small samples for SMD], can be found in the
Appendix). Instead of calculating a difference in mean val-
ues between the experimental and control groups, one can
calculate a ratio of mean values. The following uses the
natural logarithm scale to carry out such calculations, sim-
ilar to statistical procedures for binary effect measures
(risk ratio and odds ratio), due to its desirable statistical
properties [14].
For a study reporting a continuous outcome, let the mean,
standard deviation, and number of patients be denoted by
meanexp,  sdexp, and nexprespectively in the experimental
group and meancontr, sdcontr, and ncontr, respectively in the
control group. The   and the variance
(Var) of its natural logarithm is estimated as follows:
The natural logarithm transformed ratios are aggregated
across studies using the generalized inverse variance
method described in the Appendix. The pooled trans-
formed ratio is then back transformed to obtain a pooled
ratio and 95% confidence interval (CI), as follows:
Log transformation of the ratio of mean values, a non-
normally distributed function, allows this approximation
of the 95% confidence interval of this approximately nor-
mally distributed transformed function. This approach is
similar to that applied to other ratio methods such as OR
and RR, used for binary group comparison studies.
As the ratio of means method is unitless, this method can
be used irrespective of the units used in trial outcome
measures. Using the delta method limited to first order
terms results in a straightforward formula to estimate the
variance of the ratio. Second order terms would be raised
to the fourth power and are not included as they would
not increase the variance by much. For example, even
choosing simulation parameters that maximized the con-
tribution of these second order terms (ratio of the stand-
ard deviation to the mean equal to 0.7, and n = 10 patients
per trial arm [see below]), would increase the variance
estimate by less than 2.5%.
Design of the Simulation Study
The parameters and their assigned values used to simulate
continuous variable meta-analysis data sets for the indi-
vidual scenarios are shown in Table 2. The values were
chosen to be representative of typical meta-analyses
exhibiting a range of standard deviations, number of tri-
als, number of participants per trial, effect sizes, and het-
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Table 2: Parameter Values Used in the Simulated Data Sets
Varied Parameter Assigned Values
Standard Deviation (percentage of control mean value) 10%, 40%, 70%
Number of Trials 5, 10, 30
Number of Experimental and Control Patients Per Trial Arm 10, 100
Effect Size (in standard deviation units) 0.2, 0.5, 0.8
Heterogeneity of Mean Values (in standard deviation units) 0, 0.5BMC Medical Research Methodology 2008, 8:32 http://www.biomedcentral.com/1471-2288/8/32
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erogeneity. The standard deviation of the control group,
expressed as a percentage of the mean value in the control
group, was varied between 10% and 70% to reflect a nar-
row to broad distribution around the mean value. The
standard deviations of the control and experimental
groups were assumed to be equal for all simulations. The
number of trials (k) ranged from 5 to 30. The number of
patients per trial arm (n) was set to either 10 or 100 in
each of the experimental and control groups, and all trials
within each simulation were assumed to have the same
number of patients. The effect size, expressed in pooled
standard deviation units (i.e. SMD), was set at 0.2, 0.5,
and 0.8 [4].
For each simulated scenario, k simulated study means and
standard deviations were calculated from a collection of n
individual values randomly sampled from a normal distri-
bution. This was done independently for the control and
experimental groups. For the control group the normal
distribution from which values were randomly sampled
had a mean value set to 100, resulting in a standard devi-
ation of 10, 40, or 70. For the experimental group the nor-
mal distribution from which values were randomly
sampled had a mean value of [100 + (effect size) × (stand-
ard deviation)] and the same standard deviation as the
control group. Using the simulated study mean values
and standard deviations, meta-analysis was carried out
using MD, SMD, and RoM, with inverse variance weight-
ing and a random effects model as described in the
Appendix. With the parameters described above, the
expected MD = (effect size) × (standard deviation), the
expected SMD = effect size, and the expected RoM = 1 +
[(effect size) × (standard deviation)/(mean value in con-
trol group[= 100])], where effect size varies as 0.2, 0.5 and
0.8, and the standard deviation varies as 10, 40, and 70.
Heterogeneity for each scenario was introduced by setting
τ = 0.5 standard deviation units. This was achieved by
introducing an additional study-specific standard devia-
tion equal to 0.5/√2 standard deviation units to both the
experimental and the control groups, since the study-spe-
cific standard deviation of the difference between experi-
mental and control groups is given by √[(0.5/√2)2 + (0.5/
√2)2] = 0.5 standard deviation units. In other words,
study-specific variance was added to experimental and
control group means but the baseline difference and ratio
in mean values was held constant. Since a given degree of
result heterogeneity may be reflected differently in the dif-
ference methods (MD and SMD) compared to the ratio
method (RoM), heterogeneity was added at the level of
the individual mean values rather than the level of the
treatment effects to ensure that the degree of heterogene-
ity added was comparable between the three methods.
Heterogeneity of each meta-analysis scenario is presented
using I2. Since I2 = τ2/(τ2 + s2), where s2 is the variance of
the effect measure, as described in the Appendix, the
expected value for I2 for τ = 0.5 can be calculated to be
56% when n = 10 patients per trial arm, corresponding to
the introduction of a moderate (i.e. I2 = 50–75%) degree
of heterogeneity, and 93% when n = 100 patients per trial
arm, corresponding to a high (i.e. I2 > 75%) degree of het-
erogeneity [11,12].
The baseline scenarios assumed equal numbers of partici-
pants in both the experimental and control arms and were
constructed by randomly selecting data points from nor-
mally distributed data. Separate sensitivity analyses were
also carried out to determine 1) the effect of unequal
numbers of participants (chosen to have a 2:1 and 1:2
experimental:control arm ratio but keeping the total
number of participants constant (i.e. 14:6 instead of
10:10 and 134:66 instead of 100:100)) and 2) the effect
of selecting the data points from an underlying skewed
distribution. The skewed distribution was empirically
constructed by mixing a combination of 3 normal distri-
butions with identical standard deviations (0.24) cen-
tered at 0.84, 1.42 and 1.92 and weighted 77%, 17%, and
6% respectively in the overall mixed skewed distribution.
This created a graphical distribution appearing markedly
skewed on visual inspection with an overall mean of unity
and overall standard deviation similar to that of the mid-
dle normally distributed data scenario (i.e. 40% of the
control mean value), but skewness (third standardized
moment about the mean [15]) of 0.88.
For each scenario, data points were generated and ana-
lyzed 10,000 times and performance characteristics of
each effect measure were assessed. These consisted of bias
(expressed as a percentage of the true parameter value,
directed away or towards the null value [zero for MD and
SMD, and one for RoM]), coverage (of the 95% confi-
dence interval of the simulated result, i.e. the percentage
of time that the true parameter value falls within the 95%
confidence interval of the simulated result), statistical
power (the percentage of time that the 95% confidence
interval of the simulated result yields a significant treat-
ment effect, by excluding zero for MD and SMD or one for
RoM), and heterogeneity (expressed as I2). Simulations
were programmed and carried out using SAS (version 8.2,
Cary, NC).
Results
Table 3 presents simulation results for the baseline scenar-
ios (standard deviation 40% of the control mean, equal
numbers of patients in the control and experimental
groups, underlying normal distribution of the individual
data points), for each combination of effect size (0.2, 0.5,
and 0.8 standard deviation units), number of patients (10
and 100 control and experimental patients per trial), and
number of trials (5, 10, and 30). Results for similar scenar-B
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Table 3: Simulation Results (Normal Distribution, Equal Experimental and Control Groups, Standard Deviation 40% of Control Mean Value).
% Bias % Coverage % Statistical Power I2(%)
τ = 0s τ = 0.5s τ = 0s τ = 0.5s τ = 0s τ 0.5s τ 0.5s
Δ n  ( e x p / c o n t r ) kM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o M
S M D  =  0 . 2 1 0 / 1 0 50 - 4 0 0 - 5 1 9 59 7 9 59 09 2 9 01 51 1 1 41 51 3 1 45 94 8 5 5
10 0 -5 0 1 -5 0 95 97 95 92 93 92 27 22 26 19 18 19 60 48 56
30 0 -5 0 1 -6 0 94 96 95 94 94 94 66 61 64 39 38 38 60 48 56
M D  =  8 1 0 0 / 1 0 0 50 0 0 0 0 1 9 69 7 9 68 88 8 8 78 28 2 8 22 12 1 2 19 39 2 9 2
R o M  =  1 . 0 8 1 0 0 0 0 0 0 0 9 69 6 9 69 29 2 9 19 99 9 9 92 72 7 2 89 39 2 9 2
30 0 0 0 0 0 0 96 96 96 94 94 94 100 100 100 56 58 59 93 92 92
S M D  =  0 . 5 1 0 / 1 0 50 - 4 0 0 - 5 0 9 59 7 9 59 09 2 9 06 45 7 6 24 34 0 4 25 94 8 5 6
10 0 -5 0 0 -5 0 95 97 95 92 93 92 91 89 90 66 64 65 60 48 56
30 0 -5 0 0 -6 0 94 96 94 94 93 93 100 100 100 98 97 97 60 47 57
MD = 20 100/100 5 0 0 0 0 0 1 96 97 96 88 88 88 100 100 100 61 61 61 93 92 92
RoM = 1.2 10 0 0 0 0 0 0 96 96 96 92 92 91 100 100 100 85 86 86 93 92 92
30 0 0 0 0 -1 0 96 96 96 94 94 93 100 100 100 100 100 100 93 92 92
S M D  =  0 . 8 1 0 / 1 0 50 - 4 0 0 - 5 0 9 59 7 9 59 09 2 9 09 59 4 9 57 57 2 7 35 94 7 5 6
10 0 -5 0 0 -5 0 95 96 95 92 92 92 100 100 100 95 95 95 60 47 57
30 0 -5 -1 0 -6 0 94 94 94 94 92 93 100 100 100 100 100 100 60 46 57
MD = 32 100/100 5 0 0 0 0 0 1 96 96 96 88 88 87 100 100 100 91 91 91 93 92 92
RoM = 1.32 10 0 0 0 0 0 1 96 96 96 92 92 91 100 100 100 100 100 100 93 91 92
30 0 0 0 0 -1 0 96 96 96 94 94 93 100 100 100 100 100 100 93 91 92
Results of 10,000 simulations per scenario with a standard deviation equal to 40% of the control mean, for each combination of effect size (0.2, 0.5, and 0.8 standard deviation units), number of patients (10/
10 and 100/100 experimental/control patients per trial), and number of trials (5, 10, and 30). The "% Bias" columns show the bias of each effect measure (MD, SMD, RoM) expressed as percentages of the 
expected values (negative sign denotes less than expected value), with and without heterogeneity. The "% coverage" columns show the percentage of cases that the true value falls within the 95% confidence 
interval of the simulated result, with and without heterogeneity. The "% statistical power" columns show the percentage of cases that the 95% confidence interval of the simulated result yields a significant 
treatment effect (i.e. excluding zero for MD and SMD, and one for RoM), with and without heterogeneity. The I2 column shows the degree of heterogeneity only for the scenarios in which heterogeneity was 
introduced. (For all the scenarios without heterogeneity, the ratio of Q/(k-1) was close to unity as expected, corresponding to I2 = 0 [data not shown].)
Abbreviations for Table and Legend: contr – control, exp – experimental, I2 – I2 heterogeneity measure, k – number of trials in each meta-analysis, n – number of experimental or number of control patients 
per trial, Q – Cochran's Q statistic for heterogeneity, MD – mean difference, RoM – ratio of means, s – standard deviation units, SMD – standardized mean difference.BMC Medical Research Methodology 2008, 8:32 http://www.biomedcentral.com/1471-2288/8/32
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ios except with lower (10% of the control mean) or higher
(70% of the control mean) standard deviations are shown
in Tables 4 and 5. The skewed distribution results were
similar (Table 6).
Bias
The MD method exhibits minimal bias (less than 0.5%)
in almost all of scenarios. In contrast, there is one princi-
pal source of bias for the SMD method and two for the
RoM method.
SMD Bias Towards No Effect with Smaller Trials
SMD is biased towards zero or no effect, with the bias
more prominent when the number of patients per study is
small. Table 3 shows this bias to be (-)4 to 6% in the base-
line scenario with 10 patients per trial, regardless of the
number of trials. The bias decreases in the 100-patient per
trial scenarios. The lower weighting of extreme values (i.e.
values far from no effect [zero]) in the SMD method also
results in decreased heterogeneity (I2), in the scenarios
with 10 patients per trial where the bias is largest (dis-
cussed in the heterogeneity section below). Sampling var-
iance alone results in bias toward zero, but this bias is
even larger when heterogeneity is present since this results
in a further increase in dispersion (or the effective vari-
ance) of the results. These findings are consistent with the-
oretical considerations (see Appendix).
RoM Bias
In contrast, the RoM bias depends on the relative effects of
two competing sources of bias. The first is a negative bias
towards unity or no effect due to properties of the variance
of ln(RoM) and is most pronounced when the number of
patients per trial is small. The second is a bias away from
unity or no effect occurring when heterogeneity is present,
due to properties of RoM. Although bias from both
sources is absent or less than 0.5% in all scenarios with
100 patients per trial and no heterogeneity, one or both
sources of bias can be significant in other scenarios. These
are described in more detail below.
RoM Bias Towards No Effect with Smaller Trials
To understand the bias towards unity or no effect, one
must consider the factors influencing the variance of
ln(RoM) described in the Methods. As in the scenarios
studied with equal standard deviations in the control and
experimental groups, consider RoM >1, where the experi-
mental mean is greater than the control mean. In this sit-
uation the contribution of the experimental group's
relative error to the variance of ln(RoM) is smaller than
that of the control group's relative error. As RoM increases,
either the experimental mean value (meanexp) increases for
a given control mean value (meancontr) or meancontr falls for
a given meanexp. In the former case, the term (1/meanexp)2
falls and the variance of ln(RoM) becomes relatively
smaller, compared to lower RoM values. In the latter case,
the term (1/meancontr)2  increases and the variance of
ln(RoM) becomes relatively larger, compared to lower
RoM values. Because of the different relative error term
contributions discussed above, the decrease in the experi-
mental group relative error term determined by (1/mean-
exp)2 is smaller than the increase in the control group
relative error term determined by (1/meancontr)2. Thus,
when these effects are averaged, the overall effect is that
higher RoM values have a higher variance and therefore
receive relatively lower weighting in the inverse variance
weighted meta-analysis, leading to bias towards unity or
no effect. This bias is accentuated by i) larger standard
deviations, ii) higher heterogeneity (due to larger effective
standard deviations), and iii) smaller trials. The bias is
best demonstrated in the scenarios without heterogeneity
in which the standard deviation is 70% of the mean con-
trol value, the number of patients per trial is 10 and the
effect size is moderate to large, as shown in Table 5. (This
bias is also present in the scenarios with heterogeneity and
10 patients per trial shown in Table 5; however, the over-
all bias in these scenarios is due to the combined effect of
both this bias towards unity discussed in this section and
a bias away from unity discussed in the next section.)
Under these conditions, the magnitude of this bias ranges
up to 2–3%. Due to its inverse dependence on study size
it decreases to less than 0.5% in the scenarios without het-
erogeneity enrolling 100 patients per trial. The bias is also
accentuated in scenarios with either larger RoM or a ratio
of the number of patients in the experimental group to the
number of patients in the control group (nexp/ncontr) >1.
This occurs because as either meanexp increases relative to
meancontr or  nexp increases relative to ncontr, the term (1/
nexpmeanexp
2) decreases and changes in the control group
relative error predominate to an even greater extent. For
example, compare the results from scenarios without het-
erogeneity shown in Table 3 with a 1:1 experimental to
control patient ratio to those shown in Table 7 with a 2:1
experimental to control patient ratio. In contrast, increas-
ing ncont relative to nexp decreases the contribution of the
control group's relative error. This decreases the magni-
tude of the bias towards unity and can even change the
direction of the bias from negative to positive (i.e. to a
bias away from unity or no effect) if the ratio ncontr/nexp is
increased to a value greater than meanexp
2/meancontr
2
(RoM2). This is illustrated in Table 8 where ncontr/nexp = 2
and RoM2 < 2.
RoM Bias Away from No Effect Due to Heterogeneity
The second RoM bias is a bias away from unity (or no
effect) that occurs only in the scenarios with heterogeneity
and is due to the effects of heterogeneity on the RoM. It is
most apparent in the scenarios with heterogeneity with
higher standard deviations (70% of the mean control
value as shown in Table 5) when the number of patientsB
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Table 4: Simulation Results (Normal Distribution, Equal Experimental and Control Groups, Standard Deviation 10% of Control Mean Value).
% Bias % Coverage % Statistical Power I2(%)
τ = 0s τ = 0.5s τ = 0s τ = 0.5s τ = 0s τ 0.5s τ 0.5s
Δ n (exp/contr) k MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM
S M D  =  0 . 2 1 0 / 1 0 50 - 4 0 0 - 5 0 9 59 7 9 59 09 2 9 01 51 1 1 51 51 3 1 55 94 8 5 9
10 0 -5 0 1 -5 0 95 97 95 92 93 92 27 22 27 19 18 19 60 48 60
30 0 -5 0 1 -6 0 94 96 94 94 94 94 66 61 66 39 38 39 60 48 60
MD = 2 100/100 5 0 0 0 0 0 0 96 97 96 88 88 88 82 82 82 21 21 21 93 92 93
RoM = 1.02 10 0 0 0 0 0 0 96 96 96 92 92 92 99 99 99 27 27 27 93 92 93
30 0 0 0 0 0 0 96 96 96 94 94 94 100 100 100 56 58 57 93 92 93
S M D  =  0 . 5 1 0 / 1 0 50 - 4 0 0 - 5 0 9 59 7 9 59 09 2 9 06 45 7 6 34 34 0 4 35 94 8 5 9
10 0 -5 0 0 -5 0 95 97 95 92 93 92 91 89 91 66 64 66 60 48 60
30 0 -5 0 0 -6 0 94 96 94 94 93 94 100 100 100 98 97 98 60 47 60
MD = 5 100/100 5 0 0 0 0 0 0 96 97 96 88 88 88 100 100 100 61 61 61 93 92 93
RoM = 1.05 10 0 0 0 0 0 0 96 96 96 92 92 91 100 100 100 85 86 85 93 92 93
30 0 0 0 0 -1 0 96 96 96 94 94 94 100 100 100 100 100 100 93 92 93
S M D  =  0 . 8 1 0 / 1 0 50 - 4 0 0 - 5 0 9 59 7 9 59 09 2 9 09 59 4 9 57 57 2 7 45 94 7 5 9
10 0 -5 0 0 -5 0 95 96 95 92 92 92 100 100 100 95 95 95 60 47 60
30 0 -5 0 0 -6 0 94 94 94 94 92 94 100 100 100 100 100 100 60 46 60
MD = 8 100/100 5 0 0 0 0 0 0 96 96 96 88 88 88 100 100 100 91 91 91 93 92 93
RoM = 1.08 10 0 0 0 0 0 0 96 96 96 92 92 92 100 100 100 100 100 100 93 91 93
30 0 0 0 0 -1 0 96 96 96 94 94 94 100 100 100 100 100 100 93 91 93
Results of 10,000 simulations per scenario with a standard deviation equal to 10% of the control mean, for each combination of effect size (0.2, 0.5, and 0.8 standard deviation units), number of 
patients (10/10 and 100/100 experimental/control patients per trial), and number of trials (5, 10, and 30). The "% Bias" columns show the bias of each effect measure (MD, SMD, RoM) expressed 
as percentages of the expected values (negative sign denotes less than expected value), with and without heterogeneity. The "% coverage" columns show the percentage of cases that the true value 
falls within the 95% confidence interval of the simulated result, with and without heterogeneity. The "% statistical power" columns show the percentage of cases that the 95% confidence interval of 
the simulated result yields a significant treatment effect (i.e. excluding zero for MD and SMD, and one for RoM), with and without heterogeneity. The I2 column shows the degree of heterogeneity 
only for the scenarios in which heterogeneity was introduced. (For all the scenarios without heterogeneity, the ratio of Q/(k-1) was close to unity as expected, corresponding to I2 = 0 [data not 
shown].)
Abbreviations for Table and Legend: contr – control, exp – experimental, I2 – I2 heterogeneity measure, k – number of trials in each meta-analysis, n – number of experimental or number of 
control patients per trial, Q – Cochran's Q statistic for heterogeneity, MD – mean difference, RoM – ratio of means, s – standard deviation units, SMD – standardized mean difference.B
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Table 5: Simulation Results (Normal Distribution, Equal Experimental and Control Groups, Standard Deviation 70% of Control Mean Value).
% Bias % Coverage % Statistical Power I2(%)
τ = 0s τ = 0.5s τ = 0s τ = 0.5s τ = 0s τ 0.5s τ 0.5s
Δ n (exp/contr) k MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM
SMD = 0.2 10/10 5 0 -4 0 -1 -5 0 95 97 96 90 92 91 15 11 12 15 13 12 59 48 45
10 0 -5 -1 0 -5 -1 95 97 96 92 93 93 27 22 23 19 18 16 60 48 45
30 0 -5 -1 0 -6 -1 94 96 95 94 94 93 66 61 60 38 38 34 60 47 46
MD = 14 100/100 5 0 0 0 0 -1 2 96 97 96 88 88 87 82 82 82 21 21 22 93 92 91
RoM = 1.14 10 0 0 0 0 0 1 96 96 96 92 92 90 99 99 99 27 27 31 93 92 91
30 0 0 0 0 0 1 96 96 96 94 94 92 100 100 100 56 58 62 93 92 91
S M D  =  0 . 5 1 0 / 1 0 50 - 4 - 1 0 - 5 - 19 59 7 9 59 09 2 9 16 45 7 5 84 34 0 3 85 94 8 4 7
10 0 -5 -2 0 -5 -2 95 97 95 92 93 92 91 89 88 66 64 61 60 47 47
30 0 -5 -2 0 -6 -3 94 96 92 94 93 91 100 100 100 98 97 97 60 47 48
MD = 35 100/100 5 0 0 0 0 0 2 96 97 96 88 88 87 100 100 100 61 61 63 93 92 91
RoM = 1.35 10 0 0 0 0 0 1 96 96 96 92 92 90 100 100 100 85 86 88 93 92 91
30 0 0 0 0 -1 1 96 96 95 94 94 92 100 100 100 100 100 100 93 92 91
S M D  =  0 . 8 1 0 / 1 0 50 - 4 - 1 0 - 5 - 29 59 7 9 59 09 2 9 09 59 4 9 37 47 2 7 15 94 7 4 8
10 0 -5 -2 0 -5 -3 95 96 94 92 92 91 100 100 100 95 95 94 60 46 48
30 0 -5 -3 0 -6 -4 94 94 90 94 92 89 100 100 100 100 100 100 60 46 49
MD = 56 100/100 5 0 0 0 0 0 2 96 96 96 88 88 87 100 100 100 91 91 92 93 92 91
RoM= 1.56 10 0 0 0 0 0 2 96 96 96 92 92 90 100 100 100 100 100 100 93 91 91
30 0 0 0 0 -1 1 96 96 95 94 94 92 100 100 100 100 100 100 93 91 91
Results of 10,000 simulations per scenario with a standard deviation equal to 70% of the control mean, for each combination of effect size (0.2, 0.5, and 0.8 standard deviation units), number of patients 
(10/10 and 100/100 experimental/control patients per trial), and number of trials (5, 10, and 30). The "% Bias" columns show the bias of each effect measure (MD, SMD, RoM) expressed as percentages 
of the expected values (negative sign denotes less than expected value), with and without heterogeneity. The "% coverage" columns show the percentage of cases that the true value falls within the 95% 
confidence interval of the simulated result, with and without heterogeneity. The "% statistical power" columns show the percentage of cases that the 95% confidence interval of the simulated result yields 
a significant treatment effect (i.e. excluding zero for MD and SMD, and one for RoM), with and without heterogeneity. The I2 column shows the degree of heterogeneity only for the scenarios in which 
heterogeneity was introduced. (For all the scenarios without heterogeneity, the ratio of Q/(k-1) was close to unity as expected, corresponding to I2 = 0 [data not shown].)
Abbreviations for Table and Legend: contr – control, exp – experimental, I2 – I2 heterogeneity measure, k – number of trials in each meta-analysis, n – number of experimental or number of control 
patients per trial, Q – Cochran's Q statistic for heterogeneity, MD – mean difference, RoM – ratio of means, s – standard deviation units, SMD – standardized mean difference.B
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Table 6: Simulation Results (Skewed Distribution, Equal Experimental and Control Groups, Standard Deviation 40% of Control Mean Value).
% Bias % Coverage % Statistical Power I2(%)
τ = 0s τ = 0.5s τ = 0s τ = 0.5s τ = 0s τ 0.5s τ 0.5s
Δ N (exp/contr) k MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM MD SMD RoM
SMD = 0.2 10/10 5 0 -2 0 -1 -5 1 95 97 95 89 92 90 16 12 16 15 13 15 60 50 60
10 0 -3 0 0 -4 0 94 97 94 92 93 92 29 22 28 19 17 19 61 49 61
30 0 -4 0 0 -5 0 94 96 94 94 94 94 68 62 67 38 37 36 61 49 61
M D  =  8 1 0 0 / 1 0 0 50 0 0 1 0 1 9 69 6 9 68 88 8 8 88 28 1 8 22 12 1 2 19 39 2 9 2
R o M  =  1 . 0 8 1 0 0 - 1 0 0 0 0 9 69 6 9 69 29 2 9 19 99 9 9 92 72 8 2 89 39 2 9 2
30 0 0 0 0 0 0 96 96 96 94 93 93 100 100 100 56 58 59 93 92 92
SMD = 0.5 10/10 5 0 -2 1 -1 -4 1 95 97 95 89 92 90 65 59 64 43 40 42 60 49 60
10 0 -3 0 0 -4 0 94 97 94 92 93 92 92 90 91 65 63 63 61 49 61
30 0 -4 0 0 -5 0 94 96 94 94 94 94 100 100 100 98 98 98 61 48 61
MD = 20 100/100 5 0 0 0 0 0 1 96 96 96 88 88 88 100 100 100 61 61 61 93 92 92
RoM = 1.2 10 0 0 0 0 0 0 96 96 96 92 91 91 100 100 100 85 86 86 93 92 92
30 0 0 0 0 0 0 96 96 96 94 93 93 100 100 100 100 100 100 93 92 92
S M D  =  0 . 8 1 0 / 1 0 50 - 2 1 0 - 3 1 9 59 7 9 58 99 2 9 09 59 4 9 57 47 2 7 36 04 8 6 0
10 0 -3 1 0 -4 0 94 96 94 92 92 92 100 100 100 95 95 95 61 48 61
30 0 -4 0 0 -5 0 94 95 94 94 93 94 100 100 100 100 100 100 61 48 62
MD = 32 100/100 5 0 0 0 0 0 1 96 96 96 88 88 88 100 100 100 91 91 91 93 92 92
RoM = 1.32 10 0 0 0 0 0 1 96 96 96 92 92 91 100 100 100 100 100 100 93 92 92
30 0 0 0 0 0 0 96 96 96 94 93 93 100 100 100 100 100 100 93 91 92
Results of 10,000 simulations per scenario with a standard deviation equal to 40% of the control mean, for each combination of effect size (0.2, 0.5, and 0.8 standard deviation units), number of patients (10/
10 and 100/100 experimental/control patients per trial), and number of trials (5, 10, and 30) assuming a skewed distribution described in the Methods. The "% Bias" columns show the bias of each effect 
measure (MD, SMD, RoM) expressed as percentages of the expected values (negative sign denotes less than expected value), with and without heterogeneity. The "% coverage" columns show the 
percentage of cases that the true value falls within the 95% confidence interval of the simulated result, with and without heterogeneity. The "% statistical power" columns show the percentage of cases that 
the 95% confidence interval of the simulated result yields a significant treatment effect (i.e. excluding zero for MD and SMD, and one for RoM), with and without heterogeneity. The I2 column shows the 
degree of heterogeneity only for the scenarios in which heterogeneity was introduced. (For all the scenarios without heterogeneity, the ratio of Q/(k-1) was close to unity as expected, corresponding to I2 
= 0 [data not shown].)
Abbreviations for Table and Legend: contr – control, exp – experimental, I2 – I2 heterogeneity measure, k – number of trials in each meta-analysis, n – number of experimental or number of control patients 
per trial, Q – Cochran's Q statistic for heterogeneity, MD – mean difference, RoM – ratio of means, s – standard deviation units, SMD – standardized mean difference.B
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Table 7: Simulation Results (Normal Distribution, 2:1 Experimental to Control Group Sizes, Standard Deviation 40% of Control Mean Value).
% Bias % Coverage % Statistical Power I2(%)
τ = 0s τ = 0.5s τ = 0s τ = 0.5s τ = 0s τ 0.5s τ 0.5s
Δ n  ( e x p / c o n t r ) kM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o M
S M D  =  0 . 2 1 4 / 6 5 - 1- 5 0 0 - 5 0 9 49 7 9 49 09 2 9 01 51 0 1 11 41 2 1 25 94 4 5 4
10 1 -4 -1 2 -4 -1 94 97 93 92 93 91 25 18 18 18 16 14 60 44 55
30 0 -5 -1 1 -6 -1 94 97 91 93 94 93 59 53 44 36 35 27 60 44 55
M D  =  8 1 3 4 / 6 6 50 0 0 0 - 1 0 9 69 7 9 78 88 8 8 87 87 7 7 62 12 1 2 19 29 1 9 1
R o M  =  1 . 0 8 1 0 0 0 0 0 - 1 0 9 69 6 9 69 29 1 9 19 89 8 9 72 72 7 2 79 29 1 9 1
30 0 0 0 0 -1 0 96 96 96 94 94 94 100 100 100 56 57 57 92 91 91
S M D  =  0 . 5 1 4 / 6 50 - 4 - 1 0 - 5 0 9 49 7 9 49 09 2 9 05 75 0 5 04 13 7 3 65 94 4 5 4
10 0 -5 -1 1 -5 -1 94 97 93 92 93 91 86 83 79 62 61 56 60 44 55
30 0 -5 -1 0 -6 -1 94 96 91 93 93 92 100 100 100 96 97 94 60 43 56
MD = 20 134/66 5 0 0 0 0 -1 1 96 96 97 88 88 88 100 100 100 60 61 60 92 91 91
RoM = 1.2 10 0 0 0 0 -1 0 96 96 96 92 92 91 100 100 100 85 86 85 92 91 91
30 0 0 0 0 -1 0 96 96 95 94 94 94 100 100 100 100 100 100 92 91 91
S M D  =  0 . 8 1 4 / 6 50 - 4 - 1 0 - 5 0 9 49 7 9 39 09 2 9 09 18 9 8 77 16 9 6 65 94 3 5 4
10 0 -5 -1 0 -5 -1 94 96 92 92 93 91 100 100 99 93 93 91 60 43 55
30 0 -5 -2 0 -6 -1 94 94 90 93 92 92 100 100 100 100 100 100 60 42 56
MD = 32 134/66 5 0 0 0 0 -1 1 96 96 96 88 88 88 100 100 100 91 91 91 92 91 91
RoM = 1.32 10 0 0 0 0 -1 0 96 96 96 92 92 91 100 100 100 100 100 100 92 91 91
30 0 0 0 0 -1 0 96 96 95 94 94 93 100 100 100 100 100 100 92 91 91
Results of 10,000 simulations per scenario with a standard deviation equal to 40% of the control mean, for each combination of effect size (0.2, 0.5, and 0.8 standard deviation units), number of patients 
(14/6 and 134/66 experimental/control patients per trial), and number of trials (5, 10, and 30). The "% Bias" columns show the bias of each effect measure (MD, SMD, RoM) expressed as percentages of 
the expected values (negative sign denotes less than expected value), with and without heterogeneity. The "% coverage" columns show the percentage of cases that the true value falls within the 95% 
confidence interval of the simulated result, with and without heterogeneity. The "% statistical power" columns show the percentage of cases that the 95% confidence interval of the simulated result yields 
a significant treatment effect (i.e. excluding zero for MD and SMD, and one for RoM), with and without heterogeneity. The I2 column shows the degree of heterogeneity only for the scenarios in which 
heterogeneity was introduced. (For all the scenarios without heterogeneity, the ratio of Q/(k-1) was close to unity as expected, corresponding to I2 = 0 [data not shown].)
Abbreviations for Table and Legend: contr – control, exp – experimental, I2 – I2 heterogeneity measure, k – number of trials in each meta-analysis, n – number of experimental or number of control 
patients per trial, Q – Cochran's Q statistic for heterogeneity, MD – mean difference, RoM – ratio of means, s – standard deviation units, SMD – standardized mean difference.B
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Table 8: Simulation Results (Normal Distribution, 1:2 Experimental to Control Group Sizes, Standard Deviation 40% of Control Mean Value).
% Bias % Coverage % Statistical Power I2(%)
τ = 0s τ = 0.5s τ = 0s τ = 0.5s τ = 0s τ 0.5s τ 0.5s
Δ n ( e x p / c o n t r ) kM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o MM DS M DR o M
SMD = 0.2 6/14 5 1 -3 1 1 -3 2 94 97 94 90 93 90 15 10 17 14 12 16 59 44 55
M D  =  8 1 0 0 - 4 1 2 - 4 1 9 49 7 9 49 29 4 9 22 51 8 3 01 81 6 2 26 04 4 5 6
RoM = 1.08 30 0 -5 1 1 -5 1 93 97 93 94 94 93 59 53 69 36 35 44 60 44 56
66/134 5 0 0 0 0 -1 1 96 96 96 88 88 87 77 77 79 20 20 21 92 91 92
10 0 -1 0 0 -1 0 96 96 96 92 92 91 98 98 98 26 27 28 92 91 92
30 0 0 0 0 -1 0 96 96 96 94 94 94 100 100 100 56 57 59 92 91 92
SMD = 0.5 6/14 5 0 -3 1 1 -4 1 94 97 95 90 92 90 57 50 61 41 37 43 59 44 56
MD = 20 10 0 -4 1 1 -5 1 94 97 94 92 93 92 86 83 89 62 60 66 60 44 57
RoM = 1.2 30 0 -5 1 0 -6 1 93 96 94 94 94 94 100 100 100 96 97 98 60 43 57
66/134 5 0 0 0 0 -1 1 96 96 96 88 88 88 100 100 100 61 61 61 92 91 92
10 0 0 0 0 -1 0 96 96 96 92 92 91 100 100 100 84 85 86 92 91 92
30 0 0 0 0 -1 0 96 96 96 94 94 94 100 100 100 100 100 100 92 91 92
SMD = 0.8 6/14 5 0 -4 0 0 -4 1 94 97 95 90 92 90 91 89 93 72 69 74 59 43 56
MD = 32 10 0 -5 0 0 -5 1 94 96 95 92 93 92 100 100 100 93 93 94 60 43 57
RoM = 1.32 30 0 -5 0 0 -6 0 93 95 94 94 92 94 100 100 100 100 100 100 60 42 57
66/134 5 0 0 0 0 -1 1 96 96 96 88 88 88 100 100 100 90 91 91 92 91 92
10 0 0 0 0 -1 1 96 96 96 92 92 92 100 100 100 100 100 100 92 91 92
30 0 0 0 0 -1 0 96 96 96 94 94 94 100 100 100 100 100 100 92 91 92
Results of 10,000 simulations per scenario with a standard deviation equal to 40% of the control mean, for each combination of effect size (0.2, 0.5, and 0.8 standard deviation units), number of patients (6/
14 and 66/134 experimental/control patients per trial), and number of trials (5, 10, and 30). The "% Bias" columns show the bias of each effect measure (MD, SMD, RoM) expressed as percentages of the 
expected values (negative sign denotes less than expected value), with and without heterogeneity. The "% coverage" columns show the percentage of cases that the true value falls within the 95% confidence 
interval of the simulated result, with and without heterogeneity. The "% statistical power" columns show the percentage of cases that the 95% confidence interval of the simulated result yields a significant 
treatment effect (i.e. excluding zero for MD and SMD, and one for RoM), with and without heterogeneity. The I2 column shows the degree of heterogeneity only for the scenarios in which heterogeneity 
was introduced. (For all the scenarios without heterogeneity, the ratio of Q/(k-1) was close to unity as expected, corresponding to I2 = 0 [data not shown].)
Abbreviations for Table and Legend: contr – control, exp – experimental, I2 – I2 heterogeneity measure, k – number of trials in each meta-analysis, n – number of experimental or number of control patients 
per trial, Q – Cochran's Q statistic for heterogeneity, MD – mean difference, RoM – ratio of means, s – standard deviation units, SMD – standardized mean difference.BMC Medical Research Methodology 2008, 8:32 http://www.biomedcentral.com/1471-2288/8/32
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per trial is 100, since in the 100-patient per trial scenarios
the simultaneously present bias towards unity (or no
effect) discussed above is less than 0.5%. (In the scenarios
with heterogeneity and 10 patients per trial shown in
Table 5, the overall bias is due to the combined effect of
both the bias towards unity discussed in the previous sec-
tion and the bias away from unity discussed in this sec-
tion.) This bias away from unity ranges up to 1–2% in the
scenarios with 100 patients per trial and occurs for the fol-
lowing reason. Heterogeneity is introduced in the simula-
tions by shifting individual trial experimental and control
mean values upwards or downwards. As in the scenarios
presented, for RoM>1, in trials where both the experimen-
tal and control means are shifted upwards, the RoM value
is decreased, and in trials when the means are both shifted
downwards, the RoM value is increased. For upward and
downward shifts of equal magnitude, the increase in the
RoM for downward shifts is greater than the decrease in
the RoM for upward shifts. This results in a pooled RoM
value that is greater in the presence of heterogeneity and
results in the bias away from unity. Table 5 demonstrates
that this bias is higher for increasing effect sizes (i.e. larger
ratios). Comparing the results where the standard devia-
tion is higher (70% of the mean control value, Table 5) to
those where the standard deviation is lower (e.g. 40% of
the mean control value, Table 3) demonstrates that this
bias increases with increasing standard deviations due to
an increased range of individual trial RoM estimates.
Coverage
The proportion of the scenarios for which the 95% confi-
dence interval contains the true effect size is relatively sim-
ilar among the three methods for most scenarios. The
coverage is close to 95%, as expected, for the scenarios
with no heterogeneity, but decreases when heterogeneity
is introduced. The lowest coverage of 87–88% is equally
low with all three methods and occurs when heterogene-
ity is present with 5 trials and 100 patients per trial arm.
This low coverage occurs because with the degree of heter-
ogeneity in these scenarios (I2 = 92–93%) the mean values
can be widely variable. With only 5 trials, the pooled
value of these mean values can be far from the true value
and due to the large number of patients per trial the con-
fidence intervals for the individual trials are relatively nar-
row resulting in missed coverage of the true value.
Increasing the number of patients to 1000 patients per
trial arm still results in coverage rates between 87–88%
(results not shown), because the degree of missed cover-
age is dominated by the degree of heterogeneity and the
increase in I2 from 92–93% in the scenarios with 100
patients per trial arm to I2 = 99% for the scenarios with
1000 patients per trial arm is relatively small.
Statistical Power to Detect a Significant Treatment Effect
As expected, statistical power (the proportion of scenarios
yielding a significant treatment effect) increases with
increasing effect size, number of patients, and number of
trials, and decreases with more heterogeneity. Power also
decreases with imbalanced patient allocation between
groups (Tables 7 and 8) because confidence intervals are
wider compared to balanced allocation scenarios. Statisti-
cal power is similar among the three methods in most sce-
narios. In scenarios where SMD or RoM are biased
towards no effect, the power decreases compared to MD,
and in the scenarios where RoM is biased away from
unity, power increases compared to MD. Overall, the
effect of these biases is small so that the proportion of sce-
narios yielding significant treatment effects is within 5
percentage points for almost all scenarios.
Heterogeneity
For the scenarios with heterogeneity, I2 is around 55–60%
and greater than 90% for scenarios with n = 10 and n =
100 patients per trial, respectively, close to the expected
values. In scenarios where SMD and RoM are biased, I2 is
lower compared to MD, which is relatively free of bias (for
example, scenarios with 10 patients per trial in Tables 3,
4, 5 [SMD] or Table 5 [RoM]). This occurs because bias
decreases the weighting of values greatly deviating from
no effect (zero for SMD and one for RoM), decreasing I2.
In the scenarios exhibiting less bias, I2 among all methods
is similar (for example, scenarios with 100 patients per
trial in Tables 3, 4, 5).
Discussion
This study examines the use of a new effect measure for
meta-analysis of continuous outcomes that we call the
ratio of means (RoM). In this method, the ratio of the
mean value in the experimental group to that of the con-
trol group is calculated. The natural logarithm-trans-
formed delta method approximated to first order terms
provides a straightforward equation estimating the vari-
ance of the RoM for each study. Using this formulation,
we performed simulations to compare the performance of
RoM to traditionally used difference of means methods,
MD and SMD.
Each method performed well within the simulated param-
eters with low bias and high coverage, even in scenarios
with moderate or high heterogeneity. The methods had
similar statistical power to detect significant treatment
effects. SMD exhibited some bias towards zero or no
effect, especially with smaller studies, as previously
described [5,6], whereas MD was relatively bias-free. RoM
gave acceptable results, with bias usually less than 2–3%.
As discussed earlier, SMD and RoM, unlike MD, allow
pooling of studies expressed in different units and allowBMC Medical Research Methodology 2008, 8:32 http://www.biomedcentral.com/1471-2288/8/32
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comparisons regarding relative effect sizes across different
interventions. However, interpreting the results of a meta-
analysis that uses SMD to determine the expected treat-
ment effect in a specific patient population requires
knowledge of the pooled standard deviation. This infor-
mation is frequently unknown to clinicians. In contrast,
interpretation of the results of a meta-analysis that uses
RoM does not require knowledge of the pooled standard
deviation and may permit clinicians to more readily esti-
mate treatment effects for their patients. Moreover, RoM
provides a result similar in form to a risk ratio, a binary
effect measure preferred by clinicians [16]. Thus, overall
RoM may be easier for clinicians to interpret.
One limitation of RoM is that the mean values of the
intervention and control groups must both be positive or
negative, since the logarithm of a negative ratio is unde-
fined. All simulations assumed positive mean values in
both groups. This limitation may be less important for
biological variables since these generally have positive val-
ues. Another related limitation inherent to ratio methods
occurs for a normally distributed control variable with a
very broad distribution (i.e. a significant proportion of
expected negative values) or for a control variable with
only positive values but a distribution heavily skewed
towards zero. In both such distributions, a high propor-
tion of the control mean values will be very small. These
small values in the denominator of the RoM can result in
a high proportion of exceedingly large ratios. This could
generate results biased to higher values.
In addition to statistical properties, the choice between a
difference or a ratio method for a specific situation should
be determined by the biological effect of the treatment as
either additive or relative for different control group val-
ues. Unfortunately, this information is frequently not
known in advance. For binary outcomes, empirical com-
parisons between difference methods (risk difference)
and ratio methods (risk ratio and odds ratio) using pub-
lished meta-analyses have shown that the risk difference
exhibits less consistency compared to ratio methods,
resulting in increased heterogeneity [17,18]. This suggests
that for binary outcomes, relative differences are more
preserved than absolute differences as baseline risk varies.
It is unclear whether this is also the case for continuous
outcomes, but such an empirical comparison between dif-
ference and ratio methods can be performed using our
description of RoM.
Conclusion
The results of our meta-analytic simulation studies suggest
that the RoM method compares favorably to MD and
SMD in terms of bias, coverage, and statistical power. Sim-
ilar to binary outcome analysis for which both ratio and
difference methods are available, this straightforward
method provides researchers the option of using a ratio
method in addition to difference methods for analyzing
continuous outcomes.
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Appendix
This appendix briefly reviews the inverse-variance
weighted fixed and random effects models and the deter-
mination of the point estimate and variance for the con-
tinuous outcome measures, MD and SMD. The derivation
of the point estimate and variance for RoM is described in
the main text.
The inverse-variance weighted fixed and random effects 
models
In fixed effects meta-analysis, the individual studies' treat-
ment effect measures are assumed to be distributed
around the same value for each study. An estimate of thisBMC Medical Research Methodology 2008, 8:32 http://www.biomedcentral.com/1471-2288/8/32
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effect measure is obtained by taking a weighted average of
individual studies' effect measures, weighting each study
by the inverse of the variance of the effect measure used:
where ΘIV(FE) is the inverse-variance weighted fixed effects
pooled effect estimate for k total studies, Θi is the effect
measure estimate for study i, and weighting wi = 1/vari-
ance(Θi).
In random effects meta-analysis, the individual studies'
effect measures are assumed to vary around an overall
average treatment effect. An estimate of the variance of
this distribution of treatment effects, also known as
between-study heterogeneity, τ2, is incorporated into the
weights [13] to produce a summary estimate
where wi* = 1/(wi
-1 + τ2). One estimate of τ2 uses the Q sta-
tistic:
Q = Σi = 1, k wi × (Θi - ΘIV(FE))2
which has a χ2 distribution with k-1 degrees of freedom
when τ2 = 0. An estimate of τ2 follows:
When there is no between-trial heterogeneity (τ2 = 0), the
Q-statistic has the expected value of k-1, and the ratio Q/
(k-1) [12] has an expected value of unity. Under these cir-
cumstances the random effects model is equivalent to the
fixed effects model. In situations with heterogeneity (τ2 >
0), Q/(k-1)> 1, and the proportion of variation in study-
level estimates of treatment effect due to between-study
heterogeneity can be expressed using the I2  measure
expressed as a percentage. I2 can be expressed in terms of
Q and k-1, where I2 = [Q/(k-1) - 1]/[Q/(k-1)] which sim-
plifies to (Q-(k-1))/Q [12]. I2 can also be expressed as τ2/
(τ2 + s2), where s2 is the variance of the effect measure, and
s2 = Σi = 1, k wi (k-1)/[Σi = 1, k wi)2 - Σi = 1, k wi
2] [12]. When the
variance (and thus weighting) of each trial is identical, as
is the case with all the simulated scenarios in this study,
then the variance of the effect measure, or s2, reduces to
the variance of a single trial.
Thus, to carry out a random effects meta-analysis requires
calculating the effect measure and its variance for each
study to be combined. First the fixed effects pooled effect
measure is calculated, which is then used to estimate Q
and  τ2, and finally τ2 is used to estimate the random
effects pooled effect measure and its variance.
The Mean Difference Effect Measure
Using the measured values, the mean difference effect
measure for each study (MDi) is estimated as:
MDi = meanexp - meancontr
with estimated variance,
Var (MDi) = Var (meanexp) + Var (meancontr) = (sdexp/√nexp)2 
+ (sdcontr/√ncontr)2
where the subscripts "exp" and "contr" refer to the experi-
mental and control groups, respectively, mean to the mean
value, sd to the standard deviation, and n to the number
of patients in each group. The individual effect measures
and their variances are combined as described previously.
All studies need to be reported in identical units for mean
difference to be used as the effect measure.
The Standardized Mean Difference Effect Measure
When the outcome is not measured in identical units
across studies, one can use the standardized mean differ-
ence for each study (SMDi), in which the difference in the
means is divided by the pooled standard deviation. The
estimated value of SMDi is often multiplied by a correc-
tion factor to correct for bias away from zero (towards
larger effect sizes) when the number of patients in each
group is small [5], as follows:
with estimated variance,
where
The individual effect measures and their variances are
combined as described previously. As SMDi assumes more
extreme positive or negative values deviating from zero,
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Var(SMDi) increases, resulting in a smaller weighting for
such trials. This means that in general SMD is biased
towards zero or no effect [5,6]. This bias towards zero is
independent of the number of studies in the meta-analy-
sis, and decreases for larger N. Using a random effects
model instead of a fixed effects model can reduce this bias
because the between-study variance, estimated by τ2,
tends to equalize the study weights. However, this advan-
tage is offset by a lower Q (used to estimate τ2), which
depends on the inverse of the variance for each study and
therefore is also biased towards lower values. Alternate
weighting methods have been proposed to address this
bias [5,6].
Acknowledgements
The study received no specific funding. JF is supported by a Clinician Scien-
tist Award from the Canadian Institutes of Health Research (CIHR), and JB 
by CIHR Grant No. 84392. CIHR had no involvement in the conduct of this 
study.
References
1. Eggar M, Davey Smith G, Altman DG, editors: Systematic Reviews in
Health Care: Meta-Analysis in Context London: BMJ Books; 2001. 
2. Deeks JJ, Altman DG: Effect measures for meta-analysis of tri-
als with binary outcomes.  In Systematic Reviews in Health Care:
Meta-Analysis in Context Edited by: Eggar M, Davey Smith G, Altman
DG. London: BMJ Books; 2001:313-335. 
3. Deeks JJ, Altman DG, Bradburn MJ: Statistical methods for exam-
ining heterogeneity and combining results from several stud-
ies in meta-analysis.  In Systematic Reviews in Health Care: Meta-
Analysis in Context Edited by: Eggar M, Davey Smith G, Altman DG.
London: BMJ Books; 2001:285-312. 
4. Cohen J: Statistical Power Analysis for the Behavioral Sciences Second edi-
tion. Hillside, New Jersey: Lawrence Erlbaum Associates; 1988:24-7. 
5. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis Orlando, Flor-
ida: Academic Press; 1985. 
6. van den Noortgate W, Onghena P: Estimating the mean effect
size in meta-analysis: bias, precision, and mean squared
error of different weighting methods.  Behavior Research Meth-
ods, Instruments, & Computers 2003, 35:504-511.
7. Friedrich JO, Adhikari N, Herridge MS, Beyene J: Meta-analysis:
low-dose dopamine increases urine output but does not pre-
vent renal dysfunction or death.  Ann Intern Med 2005,
142(7):510-524.
8. Adhikari NKJ, Burns KEA, Friedrich JO, Granton JT, Cook DJ, Meade
MO: Nitric oxide improves oxygenation but not mortality in
acute lung injury: meta-analysis.  BMJ 2007, 334:779.
9. Sud S, Sud M, Friedrich JO, Adhikari NKJ: Effect of mechanical
ventilation in the prone position on clinical outcomes in
patients with acute hypoxemic respiratory failure: a system-
atic review and meta-analysis.  CMAJ 2008, 178:1153-1161.
10. Armitage P, Colton T, editors: Encyclopedia of Biostatistics Chichester,
United Kingdom: John Wiley & Sons; 1998:3731-3737. 
11. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring incon-
sistency in meta-analysis.  BMJ 2003, 327:557-560.
12. Higgins JPT, Thompson SG: Quantifying heterogeneity in a
meta-analysis.  Statistics in Medicine 2002, 21:1539-1558.
13. DerSimonian R, Laird N: Meta-analysis in clinical trials.  Controlled
Clinical Trials 1986, 7:177-188.
14. Fleiss JL: The statistical basis of meta-analysis.  Statistical Methods
in Medical Research 1993, 2:121-145.
15. Ghahramani S: Fundamentals of Probability 2nd edition. Upper Saddle
River, United States: Prentice-Hall; 2000:416. 
16. Schwartz LM, Woloshin S, Welch HG: Misunderstandings about
the effects of race and sex on physician's referrals for cardiac
catheterization.  NEJM 1999, 341:279-283.
17. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J: Heterogeneity and
statistical significance in meta-analysis: an empirical study of
125 meta-analyses.  Statistics in Medicine 2000, 19:1707-1728.
18. Deeks JJ: Issues in the selection of a summary statistic for
meta-analysis of clinical trials with binary outcomes.  Statistics
in Medicine 2002, 21:1575-1600.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2288/8/32/prepub